MyDrHank vs RX Bella

Strengths

• +Prices are published openly on the product pages, before any intake quiz — most compounded competitors gate the number behind a questionnaire
• +A real oral semaglutide tablet ($249/mo month-to-month) beside the weekly injection, so the needle is optional on the semaglutide line
• +The GLP-1 pages state the price stays the same at every dose, so titrating up does not raise the monthly cost
• +Six prescription lines on one account — weight loss, longevity, peptides and NAD+, sexual health, hair growth and strength — with free shipping included
• +Clean against the FDA warning-letter database: no letter on file under the brand, the entity or the domain

Where it loses points

• –Every price MyDrHank displays is the twelve-month prepay rung — its price component renders the cheapest term in the ladder, so the month-to-month rate ($259 semaglutide, $349 tirzepatide) appears on no page on the site
• –Month-to-month, it is expensive: $259 semaglutide against a $179 median across the providers here that disclose one, and $349 tirzepatide against a $249 median
• –One advertised price is purchasable at no tier — a footnote quotes "$200/mo for compounded tirzepatide" when the cheapest tirzepatide rung is $240, and the "$171/mo" beside it is the oral product's yearly rate, not injectable semaglutide's ($178)
• –An FAQ describes a twelve-month prepay rate as a plan with "no contract"
• –Compounded only and not FDA-approved — no brand Wegovy, Ozempic, Zepbound or Mounjaro lane at any price
• –The operating entity is named — Dr. Hank, LLC, credited in the privacy policy and terms of use — but nobody clinical is: no medical director or prescriber appears anywhere, no lab or monitoring program is published, and the compounding pharmacy is described only as "an FDA-registered U.S. pharmacy"
• –The trust row reads "HIPAA-aware", not HIPAA-compliant — a hedge worth noticing on a site handling prescription intake
• –No served-states list appears on the consumer site; the affiliate terms exclude Kansas, Louisiana, Mississippi, New Mexico, North Dakota and West Virginia

Strengths

• +All four programs — microdose, oral, semaglutide injection, tirzepatide injection — carry a figure on the homepage before any intake
• +Nothing in the catalog is struck through: no invented "was" price and no expiring offer
• +"$0 if you're not approved" is stated plainly and repeatedly
• +The online provider visit, prescription, delivery and ongoing check-ins are stated as included

Where it loses points

• –The hero's "from $199/mo" is the microdose; the tirzepatide program is $299
• –Every figure is a floor, no dose ladder is published, and the eight-screen intake reaches an email gate without showing a price
• –Its own treatment pages carry no dollar figure and read "AVAILABLE BY CONSULTATION"
• –No lab or monitoring requirement is published
• –The compounding pharmacies are never named and the footer names no company